Drugs Made In America Acquisition Corp. Ordinary Shares
Financial ServicesNASDAQ:DMAA · NASDAQ Global Select
+$0.01 today
Vol 0.00M · Avg 0.11M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into $6.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $0.20, tying the income statement back to per-share earnings.
Income Statement
Annual data · 2 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $776.0M | $888.0M | $1.0B |
| Cost of Revenue | $0 | $0 | $1.3B | -$1.7B | $344.8M |
| Gross Profit | $0 | $0 | $13.0B | $11.6B | $10.3B |
| Gross Margin | — | — | 17.0% | 26.4% | 45.5% |
| Research & Development | $0 | $0 | $568.8M | $1.2B | $378.4M |
| Selling, General & Admin | $2.8M +586894.7% | $480 | -$1.6B | $811.0M | $1.4B |
| Operating Expenses | $2.8M +586894.7% | $480 | $14.3B | -$15.9B | $3.6B |
| Depreciation & Amortization | $0 -100.0% | $480 | $990.2M | $419.0M | $1.2B |
| EBITDA | -$2.8M | $0 | $4.4B | $10.0B | $12.6B |
| EBITDA Margin | — | — | 18.6% | 14.3% | 10.0% |
| Operating Income | -$2.8M -587794.2% | -$479 | $10.3B | $9.0B | $10.6B |
| Operating Margin | — | — | 13.3% | 11.2% | 18.7% |
| Interest Income | $8.8M | $0 | $718.6M | $875.4M | $1.3B |
| Interest Expense | $0 | $0 | $633.2M | $801.2M | $969.2M |
| Other Income / Expenses | $8.8M | $0 | $503.0M | $368.6M | -$1.6B |
| Income Before Tax | $5.9M +1240317.7% | -$479 | $12.2B | $13.9B | -$15.6B |
| Pre-Tax Margin | — | — | 7.9% | 15.4% | 13.3% |
| Income Tax Expense | $0 | $0 | $1.2B | $375.6M | $666.8M |
| Net Income | $5.9M +1240317.7% | -$479 | $5.2B | $5.1B | $5.0B |
| Net Margin | — | — | 42.3% | 47.3% | 7.4% |
| EPS (Basic) | $0 +439.3% | -$0 | $1.4B | $591.2M | $1.2B |
| EPS (Diluted) | $0 +439.3% | -$0 | $934.2M | $777.4M | $620.6M |
| Weighted Avg Shares | $21.0M +145.1% | $8.6M | $556.2M | $724.2M | $892.2M |
| Weighted Avg Shares (Diluted) | $21.0M +145.1% | $8.6M | $812.4M | $566.0M | $319.6M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Berto Acquisition Corp.
NASDAQ:TACO
$389.82M
Centurion Acquisition Corp.
NASDAQ:ALF
$387.41M
Berto Acquisition Corp. Unit
NASDAQ:TACOU
$374.49M
Titan Acquisition Corp.
NASDAQ:TACH
$358.80M
Oyster Enterprises II Acquisition Corp
NASDAQ:OYSE
$348.64M
SIM Acquisition Corp. I
NASDAQ:SIMA
$333.96M
Renatus Tactical Acquisition Corp I Class A Ordinary Shares
NASDAQ:RTAC
$323.77M
Live Oak Acquisition Corp. V Class A Ordinary Shares
NASDAQ:LOKV
$291.53M
Mountain Lake Acquisition Corp.
NASDAQ:MLAC
$96.70M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does DMAA generate?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) reported $0.00 of revenue in fiscal 2025.
Is DMAA profitable?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) reported $5.94M of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.